Author:
Nanah Abdelrahman,Al Hadidi Samer
Abstract
Belantamab mafodotin is an antibody drug conjugate directed against B-cell maturation antigen and was approved by the Food and Drug Administration under accelerated approval for use in the US in August 2020 for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug. In November 2022 belantamab mafodotin was withdrawn from the US market after failure of a required confirmatory trial. In our review, we provide a systematic review on the use of belantamab mafodotin efficacy and safety in a real-world setting.
Publisher
Jordanian American Physician Academy
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献